Page 53 - Human Use News Today

ABRYSVO is the first and only RSV vaccine approved in the European Union for both older adults and for immunization of pregnant individuals to help protect their infants immediately from birth...

First and only U.S. approval of a maternal vaccine to help protect infants at birth through six months of life from lower respiratory tract disease and severe LRTD due to RSV FDA’s decision is...

TOKYO, Aug. 18, 2023 /PRNewswire/ -- Astellas Pharma Inc. , today announced the European Medicines Agency has accepted for regulatory review the marketing authorization application for...

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) said the European Medicines Agency (EMA) has accepted for regulatory review the marketing authoriz...

Ipsen heralded the greenlight of the treatment, which reduces new, abnormal bone formation in soft and connective tissues for people living with FOP.

EscharEx® Phase III study protocol:FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry ...

EscharEx® Phase III study protocol: FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders NexoBrid® U.S. commercial launch timing not

14.08.2023 - Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD) ISELIN, N.J., Aug. 14, 2023 (GLOBE ...

RADIUS RETAINS THE RIGHTS TO RECEIVE OVER $200 MILLION IN COMMERCIAL MILESTONES Boston, Mass. - Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. , a specialty... -Today at 11:27 am- MarketScreener

/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, the FDA issued an...